759456-60-5

Usage

Uses

Used in Pharmaceutical Synthesis:
(5-amino-2-morpholinophenyl)methanol is used as a key intermediate in the synthesis of pharmaceuticals for its unique functional groups and structural properties.
Used in Organic Chemical Reactions:
(5-amino-2-morpholinophenyl)methanol serves as a versatile intermediate in various organic chemical reactions, facilitating the formation of complex organic molecules.
Used in Medicinal Applications:
(5-amino-2-morpholinophenyl)methanol is being studied for its potential biological activity and is explored for its use in medicinal applications due to its unique chemical structure and functional groups.

InChI:InChI=1/C11H16N2O2/c12-10-1-2-11(9(7-10)8-14)13-3-5-15-6-4-13/h1-2,7,14H,3-6,8,12H2

Upstream product

• 300665-25-2 (2-morpholin-4-yl-5-nitrophenyl)methanol 
• 83909-55-1 methyl 2-(N-morpholino)-5-nitrobenzoate 
• 30742-62-2 2-(N-morpholinyl)-5-nitrobenzaldehyde 
• 27996-87-8 2-fluoro-5-nitrobenzaldehye 
• 63878-73-9 (2-fluoro-5-nitrophenyl)methanol 
• 65989-45-9 5-amino-2-morpholin-4-yl-benzoic acid 
• 2965-22-2 methyl 2-fluoro-5-nitro-benzoate 
• 4031-84-9 methyl 5-amino-2-(4-morpholino)benzoate 

Downstream Products

• 957346-19-9 3-(tert-butyl-dimethyl-silanyloxymethyl)-4-morpholin-4-yl-phenylamine 
• 852700-13-1 5-acetylamino-2-morpholinobenzyl acetate 
• 1187660-24-7 C₂₁H₂₂N₄O₃ 
• 1187660-40-7 C₂₇H₃₃N₅O₄ 
• 1187660-23-6 C₂₉H₃₇N₅O₅ 
• 1187660-52-1 C₂₂H₂₁N₅O₂ 
• 1071217-84-9 7-chloro-N-[4-morpholino-3-(pyrrolidinomethyl)phenyl]quinolin-4-amine 
• 1312291-25-0 N-{3-[(tert-butylamino)methyl]-4-morpholinophenyl}-7-chloroquinolin-4-amine 
• 1312291-27-2 7-chloro-N-[4-morpholino-3-(morpholinomethyl)phenyl]quinolin-4-amine 
• 1312291-24-9 7-chloro-N-{3-[(4-methylpiperazino)methyl]-4-morpholinophenyl}quinolin-4-amine 
• 1312291-23-8 {5-[(7-chloroquinolin-4-yl)amino]-2-morpholinophenyl}methanol hydrochloride 
• 1312291-26-1 7-chloro-N-[3-({[2-(dimethylamino)ethyl](methyl)amino}methyl)-4-(morpholin-4-yl)phenyl]quinolin-4-amine 
• 1187660-69-0 C₃₈H₅₂N₆O₆ 
• 1187661-06-8 C₃₇H₅₁N₇O₅ 

Relevant academic research and scientific papers

7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS

The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.

Optimized and convergent synthesis of potent anti-malarial aminoquinoline compounds: Easy access to analogs

Amodiaquine is one of the most active antimalarial 4-aminoquinoline. Previously we have described new analogs of amodiaquine and amopyroquine, in which the hydroxyl group was replaced by various amino groups and identified highly potent compounds. Here we

4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS

The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y1, m, n, R1; X1; X2; R2; X3; X4; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS

The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, formula (I), wherein R1; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF

The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula ( I ) represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES

Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following (formula I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: Benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety

Following the discovery of JTK-109 (1) as a potent inhibitor of hepatitis C virus NS5B RNA-dependent RNA polymerase, [(a) Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. J. Med. Chem. 2006, 49, 4721. (b) Hashimoto, H.; Mizutani, K.; Yoshida, A. Int. Patent Appl. WO 01/47883, 2001.] further studies toward the improvement of the cellular potency have been performed. A greater than 40-fold improvement was achieved through replacing the biphenyl moiety with a 2-morpholinophenyl group and the benzimidazole ring with the tetracyclic scaffold to afford compound 7 with an excellent replicon potency (EC50 = 7.6 nM).

5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR

The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and